- ASSOCIATE PROFESSOR | Medicine, Cardiology
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. DuBois is an articulate and exceptionally trained physician with a particular interest in managing hypertension and coronary artery disease. Dr. DuBois' patients love his thorough nature and attention to detail as well as his tech savvy approach to communication and treatment. He enjoys sailing and hockey.
Dr. DuBois graduated magna cum lade from Harvard University before receiving his Doctor of Medicine from Cornell University Medical Center in 1999, and he completed his residency at Montefiore Hospital. Following his residency, Dr. DuBois completed his fellowship in Cardiology at the Cleveland Clinic Foundation. Dr. DuBois is board certified in Internal Medicine, Cardiovascular Disease, and Nuclear Cardiology. In addition to his role as an Associate Professor at Mount Sinai, Dr. DuBois is also on staff at Lenox Hill Hospital.
- Cardiovascular Disease
- General Cardiology
- Nuclear Cardiology
MS, Harvard University
MD, Cornell University Medical College
Residency, Internal Medicine
AICOM / Montefiore Medical Center
Cleveland Clinic Foundation
American Heart Association Summer Fellowship, Honorable Mention
Davidoff Society Teaching Prize
Harvard College Scholar
- Cleveland Clinic Foundation
Lab research with Dr. Christine Moravec, Department of Cardiology. Studied changes of G-protein expression in myocardium pre and post LVAD therapy.
- Albert Einstein College of Medicine
Philadelphia, PA 2000-2002
Lab Research with Dr. Thierry Le Jemtel, Division of Cardiology. Developed a novel technique for quantitative evaluation of inflammatory marker expression within endothelial cells.
- New York Hospital
New York, NY 1998
Research Assistant for Dr. Richard Devereux, Division of Cardiology. Analyzed economic implications of current management techniques in a cohort of over 200 patients with the Marfan syndrome.
- Rogosin Institute, New York Hospital
New York, NY 1996
Lab Assistant for Dr. Manikkam Suthanthiran, Division of Nephrology. Studied novel uses of Cyclosporin A and FK506 for induction of allograft-specific tolerance in transplant patients.
- Channing Laboratory at Harvard Medical School
Boston, MA 1993-1995
Lab Assistant for Dr. James Michel and Dr. Dennis Kasper, Division of Infectious Disease. Research for honors thesis in Biology. Cloned and characterized a novel surface protein of group B Streptococcus (GBS) and established it as a viable target for a vaccine. The data was presented at an international conference on GBS, resulting in new nomenclature for GBS.
- Brigham and Women’s Hospital
Boston, MA 1993-1994
Research Coordinator for Dr. Matthew Liang, Division of Rheumatology, and Dr. James Michel, Division of Infectious Disease. Studied reactive arthritis following outbreaks of enteric pathogens.
Colombo PC, Ashton AW, Celaj S, Talreja A, Banchs JE, Dubois NB, Marinaccio M, Malla S, Lachmann J, Ware JA, Le Jemtel TH. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. Journal of applied physiology (Bethesda, Md. : 1985) 2002 Mar; 92(3).
Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH. Endothelial cell activation in patients with decompensated heart failure. Circulation 2005 Jan; 111(1).
Colombo PC, DuBois NB, Celaj S, Branchs J, Lachman J, Malla S, Jorde U, Ware JA, LeJemtel TA. Enhanced oxidative stress in vascular endothelial cells of patients with decompensated chronic heart failure. Response to short-term inotropic therapy. [abstract]. AHA. 2001;.
Colombo PC, Malla S, Talreja A, Branchs J, Lachman J, Celaj S, DuBois NB, LeJemtel TA, Ware JA. Short-term inotropic therapy produces sustained improvement in vascular endothelial function, but not in doppler-derived +dP/dT and -dP/dT in patients with severe chronic heart failure. [abstract]. AHA. 2001;.
DuBois NB, Michel JL. Novel surface protein of group B Streptococcus. Poster, Brigham and Women's Hospital Research Day 1995.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.DuBois did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.